Markets:

Overview

News

Currencies

International

Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

14.20 -0.17 (-1.22%)

Streaming Delayed Price Updated: 11:01 AM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Contineum Therapeutics, Inc. - Common stock

< Previous 1 2 Next >

Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential ↗

Today 8:03 EDT

Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent...

Via MarketBeat

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference

May 12, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

May 11, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics (NASDAQ:CTNM) Reports Q4 2025 Loss, Highlights Clinical Progress and Extended Cash Runway ↗

March 05, 2026

Via Chartmill

Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

May 05, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 01, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain

April 30, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

March 05, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

March 03, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 18, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 28, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

December 11, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

December 11, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

November 24, 2025

From Contineum Therapeutics

Via Business Wire

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

November 20, 2025

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

November 20, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

October 30, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 24, 2025

Via Benzinga

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

September 18, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at September Investor Conferences

August 28, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 19, 2025

Via Benzinga

Contineum (CTNM) Q2 R&D Jumps 78% ↗

August 05, 2025

Via The Motley Fool

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

August 05, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 22, 2025

Via Benzinga

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

June 25, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 15, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.